Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)

This study has been terminated.
(side effect profile did not match expectations)
Information provided by:
elbion AG Identifier:
First received: February 22, 2007
Last updated: August 7, 2007
Last verified: August 2007
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: August 2007
  Estimated Primary Completion Date: No date given